Skip to Content

Zinbryta (daclizumab) Disease Interactions

There are 5 disease interactions with Zinbryta (daclizumab):

Major

Daclizumab (applies to Zinbryta) depression

Major Potential Hazard, Moderate plausibility.

Depression-related events, including suicidal ideation or suicide attempt, have been reported with the use of daclizumab. If severe depression and/or suicidal ideation is present, consider discontinuation of therapy. Caution is recommended when using this agent in patients with previous depressive disorders.

Major

Daclizumab (applies to Zinbryta) infections

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Infections of the upper respiratory tract, urinary tract, and viral infections, sometimes serious, have been reported with the use of daclizumab. It is recommended to avoid daclizumab in patients with a severe active infection. Monitor for signs and symptoms of an infection and consider withholding treatment until the infection resolves.

Major

Daclizumab (applies to Zinbryta) liver disease

Major Potential Hazard, Moderate plausibility.

Daclizumab use can cause life-threatening severe liver injury, including liver failure and autoimmune hepatitis. The use of daclizumab is contraindicated in patients with a history of autoimmune hepatitis or other autoimmune condition involving the liver, and in patients with preexisting liver disease of hepatic impairment, including ALT or AST at least two times the upper limit of normal. Prior to starting therapy with daclizumab, it is recommended to obtain serum transaminases (ALT and AST) and total bilirubin levels in all patients. Continue to monitor levels of transaminase levels and total bilirubin monthly, before each next dose, and follow transaminase levels and total bilirubin monthly for 6 months after the last dose of daclizumab. Treatment modifications are recommended based on serum transaminase and total bilirubin values. If patients develop clinical signs or symptoms suggestive of hepatic dysfunction, immediately discontinue treatment and promptly measure serum transaminases and total bilirubin. Discontinue treatment if autoimmune hepatitis is suspected.

Major

Daclizumab (applies to Zinbryta) tuberculosis

Major Potential Hazard, Moderate plausibility. Applicable conditions: Tuberculosis -- Active, Tuberculosis -- Latent

Tuberculosis has been reported with the use of daclizumab in countries where tuberculosis is endemic. Prior to initiating treatment, it is recommended to evaluate high-risk patients for tuberculosis infection. Patients testing positive for tuberculosis should be treated according to standard medical practice before initiating treatment with daclizumab.

Moderate

Daclizumab (applies to Zinbryta) skin reactions

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Psoriasis, Eczema

Serious skin reaction, including photosensitivity reactions, have occurred in patients treated with daclizumab. It is recommended to use daclizumab with caution in patients with a history of skin conditions, including eczema or psoriasis, as the use of this agent may exacerbate those conditions. If a patient develops a serious diffuse or inflammatory rash, it is recommended to evaluate the patient before the next dose and to discontinue treatment as appropriate.

Zinbryta (daclizumab) drug interactions

There are 375 drug interactions with Zinbryta (daclizumab)

Zinbryta (daclizumab) alcohol/food interactions

There is 1 alcohol/food interaction with Zinbryta (daclizumab)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.